Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Read more about Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Read more about Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use? Read more about Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Read more about Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Read more about Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Read more about A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Maintenance lenalidomide in primary CNS lymphoma. Read more about Maintenance lenalidomide in primary CNS lymphoma.
Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Read more about Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications.
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Read more about Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Read more about Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
